KSKayla Simeone

Kayla Simeone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kayla Simeone has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors

    by Kayla Simeone, Robin Guay-Lord, Mohammad Abdul Lateef, Benjamin Péant, Jennifer Kendall-Dupont, Adriana Mari Orimoto, Euridice Carmona, Diane Provencher, Fred Saad, Thomas Gervais, et al.

    There is an urgent need and strong clinical and pharmaceutical interest in developing assays that allow for the direct testing of therapeutic agents on primary tissues. Current technologies fail to provide the required sample longevity, throughput, and integration with standard clinically proven assays to make the approach viable. Here we report a microfluidic micro-histological platform that enables ex vivo culture of a large array of prostate and ovarian cancer micro-dissected tissue (MDT) followed by direct on-chip fixation and paraffination, a process we term paraffin-embedding lithography (PEL). The result is a high density MDT-Micro Array (MDTMA) compatible with standard clinical histopathology that can be used to analyse ex vivo tumor response or resistance to therapeutic agents. The cellular morphology and tissue architecture are preserved in MDTs throughout the 15 day culture period. We also demonstrate how this methodology can be used to study molecular pathways involved in cancer by performing in-depth characterization of biological and pharmacological mechanisms such as p65 nuclear translocation via TNF stimuli, and to predict the treatment outcome in the clinic via MDT response to taxane-based therapies.


  • The use of a microfluidic chip platform for the ex vivo rapid measurement of chemotherapeutic responses in 3D sub millimeter biopsy samples.

    by Muhammad Abdul Lateef, Benjamin Péant, Euridice Carmona, Nassim Rousset, Kayla Simeone, Jennifer Kendall-Dupont, Adriana Mari Orimoto, Anne-Marie Mes-Masson, Thomas Gervais, Fred Saad

    E16621 Background: Evaluating prostate cancer response to therapy can often take 3 months and decisions should not be made before that time according to PCWG2 recommendations. Early response predictor identification is a major objective towards personalized medicine. The emergence of microfluidic devices has allowed for ex vivo response measurement to a given therapy in 3D tumor tissue. We have optimized a method to obtain micro-dissected tissues (MDTs) from patient biopsies, with a viability that is maintained for 14 days. Using a microfluidic, on-chip system, we studied the ex-vivo response of the MDTs to a given chemotherapeutic drug by flow cytometry. Methods: We have developed a method to precisely section biopsies into MDTs of sub-millimeter size. We have also designed a microfluidic chip, capable of trapping 25 MDTs, in which they can be exposed to different drugs. With our novel approach, we have initiated drug testing on patient samples using different combinations of Docetaxel alone (100 nM) or in combination with bicalutamide (1 mM). The treatment regimen was initiated after 24-48 hr of tissue recovery, post-surgery. The following cycles of treatment was performed on chip: 1st treatment for 24 hr, 1st recovery for 48 hr, 2nd treatment for 24 hr, 2nd recovery for 48 hr., then cell viability analysis. Results: After 24 hr in culture we observed more than 85% viability of MDTs. We observed a variable response in individual patient samples treated with per protocol on chip (less than 65% to 100% survival). For each patient included in our study, we predicted a personalized potential drug response profile based on the ex vivo response to tested drugs. We are presently comparing these profiles to the clinical response to ongoing therapy in these patients. Conclusions: The ex-vivo drug response of MDTs from patient biopsy samples on chip can be performed in a time effective manner and may eventually contribute to a more personalized approach to clinical decision making.